VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health for U.S., European and other world markets. The company has two late-stage clinical development programs in progress that target diabetes and sleep apnea. VVUS has two currently approved products: Qsymia, for chronic weight management; and Stendra, for the treatment of erectile dysfunction (ED). For more information visit the company’s Web site at www.vivus.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: